High cancerous inhibitor of PP2A (CIP2A) protein levels at diagnosis of chronic myeloid leukaemia (CML) are predictive of disease progression in imatinib-treated patients. It is not known whether this is true in patients treated with second generation tyrosine kinase inhibitors (2G TKI) from diagnosis, and whether 2G TKIs modulate the CIP2A pathway. Here, we show that patients with high diagnostic CIP2A levels who receive a 2G TKI do not progress, unlike those treated with imatinib (P =o 0.0001). 2G TKIs induce more potent suppression of CIP2A and c-Myc than imatinib. The transcription factor E2F1 is elevated in high CIP2A patients and following 1 month of in vivo treatment 2G TKIs suppress E2F1 and reduce CIP2A; these effects are not seen with imatinib. Silencing of CIP2A, c-Myc or E2F1 in K562 cells or CML CD34+ cells reactivates PP2A leading to BCR-ABL suppression. CIP2A increases proliferation and this is only reduced by 2G TKIs. Patients with high CIP2A levels should be offered 2G TKI treatment in preference to imatinib. 2G TKIs disrupt the CIP2A/c-Myc/E2F1 positive feedback loop, leading to lower disease progression risk. The data supports the view that CIP2A inhibits PP2Ac, stabilising E2F1, creating a CIP2A/c-Myc/E2F1 positive feedback loop, which imatinib cannot overcome.
INTRODUCTION
Chronic myeloid leukaemia (CML) is a malignant disease of the primitive haematological cell in which a reciprocal translocation between chromosomes 9 and 22 creates the fusion gene BCR-ABL1 which is the molecular hallmark of the disease. 1 CML treatment has been significantly improved by the tyrosine kinase inhibitor (TKI) imatinib, but at least one-third of patients will eventually fail imatinib treatment 2,3 and a significant proportion of these will progress towards blast crisis (BC), which is usually rapidly fatal. Impairment of PP2A activity by its negative regulators SET and cancerous inhibitor of PP2A (CIP2A) has an important role in the pathogenesis and progression of CML. 4, 5 CIP2A protein is associated with increased proliferation in several human malignancies [6] [7] [8] [9] [10] and its overexpression can cause cellular transformation. 7, 11 High levels are an adverse prognostic indicator in many malignancies including AML, 12 breast, 8, [13] [14] [15] bladder, 16 cervical, 17, 18 gastric, 19 and lung cancers. 10, 20, 21 In CML, we have shown that high levels of CIP2A protein at chronic phase diagnosis is a strong prospective predictor of subsequent development of BC. 5 CIP2A functions by preventing PP2A-driven dephosphorylation of c-Myc at residue serine 62, which results in stabilisation of c-Myc. 2, 7, 9, 15 SET also inhibits c-Myc degradation. 22 c-Myc is essential for BCR-ABL-mediated cellular transformation 23 and is overexpressed at transformation to BC. 24 In CML, elevated levels of c-Myc may promote aneuploidy, contributing to disease progression. 25, 26 Furthermore, protein levels of c-Myc at diagnosis correlate with imatinib treatment response. 5 E2F1 is a transcription factor which is overexpressed in CML. 27 E2F proteins are involved in cell-cycle regulation by controlling genes required for cell-cycle progression at the G1/S checkpoint. 28 E2F1 transcriptionally regulates CIP2A 8 and c-Myc. 29 E2F1 activates cell cycle and overexpression of E2F1 results in uncontrolled cellular proliferation. 30 There is cross-talk between E2F transcription factors, as depletion of E2F1 has no effect and E2F1-deficient mouse embryos develop normally. 31 E2F1 activity can be regulated by phosphorylation on residue serine 364, which is controlled by PP2A. 32 When phosphorylated, E2F1 is stabilised and cannot be degraded. In addition to phosphorylation, E2F1 transcriptional activity can be negatively regulated via the p53/p21/Rb pathway. 8, 32, 33 We have previously shown that patients with a high CIP2A protein level at diagnosis and treated with imatinib have a 100% actuarial risk of progressing to BC. 5 However, the second generation TKIs (2G TKIs) dasatinib and nilotinib are now increasingly used for first-line CML treatment and both drugs may have superior clinical outcomes compared with imatinib. 34, 35 It is not known whether high CIP2A levels confer a poor prognosis in patients treated with a 2G TKI at initial diagnosis or whether the 2G TKIs modulate the CIP2A pathway. In this study, we assessed the clinical outcome of 74 patients treated with imatinib or a 2G TKI (dasatinib or nilotinib) in relation to their diagnostic CIP2A level. Here, we confirm our earlier report that imatinib-treated patients with high diagnostic CIP2A have a high risk of developing BC, in a larger cohort with longer follow-up. We also report that, in contrast, patients with high diagnostic CIP2A do not progress to BC if treated with a 2G TKI. We show that this benefit is because unlike imatinib, 2G TKIs suppress CIP2A, leading to decreased c-Myc and E2F1, reactivation of PP2A, a decrease in BCR-ABL tyrosine kinase activity and reduced cellular proliferation.
PATIENTS AND METHODS

Patient cohort
The study was approved by the Liverpool Central Research Ethics Committee; all 74 patients gave informed consent and were aged ⩾ 18. All have been seen since original diagnosis of chronic phase CML at our centre and have been followed for at least 9 months (median follow-up: 50 months). Patient characteristics are shown in Table 1 . Patients were diagnosed between 2005 and 2013 and we include all patients who progressed during this time.
Sample collection and preparation
At diagnosis and after 1 month of TKI treatment, mononuclear cells (MNC) from chronic phase CML patients were separated by density-dependent centrifugation (Lymphoprep Axis-Shield, Oslo, Norway), washed in RPMI 1640 (BioSera, Uckfield, UK) and resuspended in 10% dimethylsulphoxide (DMSO)/10% foetal calf serum (BioSera)/RPMI at 4°C. Wherever possible, samples were enriched for CD34+ cells using the CliniMACS kit (Miltenyi Biotec, Bisley, UK).
Measurement of CIP2A, PP2Ac, phosphorylated PP2A, c-Myc and E2F1
Flow cytometry methodology has been previously described 5, 36 and was used for the detection of PP2Ac, PP2A Y307 , CIP2A, c-Myc, c-Myc S62 , E2F1 and E2F1 S364 . The following antibodies were used: Anti-PP2A catalytic subunit (Merck Millipore, Feltham, UK), PP2A Y307 (Epitomics, Burlingame, CA, USA), CIP2A, E2F1 and E2F1 S364 (Santa Cruz Biotechnology, Dallas, TX, USA), c-Myc (New England Biolabs, Hitchin, UK), c-Myc S62 (Abcam, Cambridge, UK), anti-mouse and anti-rabbit Alex fluor 488 (Invitrogen, Paisley, UK). Levels of pCrKL and CrKL were used as an assay of BCR-ABL1 activity, measured by flow cytometry as previously described. 36 CIP2A status CIP2A protein level was assessed by flow cytometry as described above and previously. 5 In this study the diagnostic CIP2A protein level (mean fluorescence intensity (MFI)) for all 74 patients was calculated ( Supplementary Table 1 ). This range was 0-52, the interquartile range was 0.48-8.65, the median was 2.85 and the mean was 6.5. High CIP2A patients are defined as those patients with a CIP2A level ⩾ 7.3. The cut-off value was derived using receiver operating characteristics (ROC) curve analysis for the prediction of BC based on the diagnostic CIP2A protein level; minimisation of the Euclidian distance between the ROC curve and the corner (0, 1) was the criterion used. The optimal cut-off value produced an AUC ROC = 0.902 (95% confidence interval (CI): 0.832, 0.973).
c-Myc protein and phosphorylation status
Briefly, whole-cell lysates were prepared from MNC using NP40 lysis buffer as previously described. 5 In vitro TKI or PP2A activation assay The effect of TKIs or PP2A activation was examined using MNC at a density of 2 x 10 6 per ml and were cultured either untreated or with 5 μM imatinib or 150 nM dasatinib or 5 μM nilotinib, or 2.5 μM FTY720 for 24 h.
PP2A activity assay PP2A phosphatase assays were carried out using the PP2A IP phosphatase assay kit (Millipore, Abingdon, UK). An optimised manufacturer's protocol for this assay was kindly provided by Professor Danilo Perrotti, University of Maryland, Maryland, USA.
Small interfering RNA (siRNA) treatment K562 or CD34+ cells were transfected using Nucleofector Kit V using the Amaxa instrument (Lonza, Basel, Switzerland). After nucleofection cells were cultured for 72 h prior to analysis. The following siRNAs were used: control siRNA, CIP2A and E2F1 (Santa Cruz Biotechnology), c-Myc siRNA (Thermo Scientific, USA).
CIP2A overexpression
K562 cells were transfected using pCMV6AC-CIP2A-green fluorescent protein (pCMV6AC-CIP2A-GFP) or pCMV6AC-GFP (OriGene, Rockville, MD, USA) as a control, using the Nucleofector Kit V using the Amaxa instrument. After nucleofection, cells were cultured for 72 h prior to analysis.
Measurement of bromodeoxyuridine (BrdU) incorporation
Cellular proliferation was assessed using a BrdU cell proliferation ELISA (Roche Diagnostics, Burgess Hill, UK). Briefly, 1 × 10 5 cells were incubated with BrdU for 24 h. Cells were then fixed and DNA denatured, anti-BrdU-POD antibody was added, cells washed and incubated with 3,3',5,5'-tetramethylbenzidine. The reaction was stopped by addition of sulphuric acid. The plate was read at 450 nM.
Statistical analysis
Statistical analysis and comparisons were performed using the statistical programme SPSS 16.0 (SPSS Inc., New York, NY, USA) and R (R Core Team 2013, Vienna, Austria). Continuous variables were summarised by descriptive statistics (median, interquartile range and range) while frequencies and percentages were calculated for categorical data. For continuous variables, the Mann-Whitney U-test was used for comparisons between independent samples and the Wilcoxon signed-rank test was used for paired data; for categorical variables Fisher's exact test was used. Overall and progression-free survival functions were estimated by the Kaplan-Meier estimator and the log-rank test was used for comparisons between groups. Cumulative incidence functions adjusted for the competing risk of death/progression were estimated for time to complete cytogenetic response (CCR), major molecular response (MMR) and MR4 and differences across groups were assessed using Gray's test. All tests were two sided at a 5% significance level. No adjustment for multiple testing was performed while no missing data imputation was required since the analysed data set was complete. For patients with high diagnostic CIP2A level treated with imatinib, the overall and progression-free survival probability at 24 months was estimated to be 41% (95% confidence interval (95% CI): 6-75%) and 17% (95% CI: 1-51%), respectively, compared with 100% for patients in any other group (P o 0.001, Figure 1 ). Disease progression to BC only occurred in those patients with a high diagnostic level of CIP2A and who were treated with imatinib. All progressions occurred within 32 months from diagnosis with the median time to progression being 12.5 months (interquartile range: 10.3-20.15). Progression was not associated with the development of BCR-ABL kinase domain mutations.
The estimated cumulative incidence functions of cumulative CCR rate is presented in Figure 2a ; for low CIP2A level imatinib-treated patients at 18 months was 85% (95% CI: 70-95%). Only one patient with a high diagnostic CIP2A level and treated with imatinib achieved a CCR (P o 0.001); this patient subsequently progressed. Again, this deleterious effect of high CIP2A was not seen if patients were treated with a 2G TKI from diagnosis, where the estimated cumulative CCR rate at 18 months was 86% (95% CI: 68-96%) and 56% (28-86%) for the low and high CIP2A 2G TKI patients, respectively. A similar trend was observed in time to major molecular response, as shown in Figure 2b .
The cumulative rate of MR4 (BCR-ABL1 transcript level of ⩽ 0.01%) for low CIP2A imatinib-treated patients was 16% (95% CI: 7-34%) at 18 months. No patient with a high diagnostic CIP2A level and treated with imatinib achieved MR4 (P = 0.008, Figure 2c ). High CIP2A patients treated with a 2G TKI have a lower rate of MR4 compared with the low CIP2A 2G TKI-treated patients, at 11% and 48% at 18 months respectively. High diagnostic CIP2A levels in patients treated with a 2G TKI predict poor molecular response (P = 0.019).
Early molecular response (BCR-ABL1/ABL1 ratio of o10% at 3 months) is an excellent predictor of clinical outcome in imatinibtreated patients. [37] [38] [39] CIP2A patients achieved an early molecular response, compared with only 9% of high CIP2A patients (P = 0.01, Figure 2d ). Ninety percent of low CIP2A patients treated with a 2G TKI achieved an early molecular response compared with 44% of those with a high CIP2A level. These data demonstrate that patients with high CIP2A and treated with a 2G TKI have a higher rate of achieving an early molecular response. In summary, patients with high diagnostic CIP2A levels and treated with a 2G TKI at initial diagnosis do not progress to BC and have a similar clinical outcome to low CIP2A patients.
2G TKIs but not imatinib suppress the CIP2A pathway We investigated if the superior clinical outcome in the high CIP2A 2G TKI cohort could be explained by the 2G TKIs modulating the CIP2A pathway. MNC from 20 newly diagnosed chronic phase CML patients were treated with the three TKIs for 24 h in an in vitro assay. CIP2A levels significantly decreased in high CIP2A patients following dasatinib or nilotinib treatment (P = 0.007 and P = 0.001, respectively), but imatinib had no significant effect (Figure 3a ). This 2G TKI associated decrease in CIP2A was accompanied by a significant decrease in c-Myc following dasatinib and nilotinib treatment (P = 0.002, Figure 3b ). All three TKIs decreased c-Myc and c-Myc S62 levels compared with untreated control; however, dasatinib and nilotinib also caused a significant decrease beyond that achieved with imatinib (P = 0.03 and P = 0.008 for c-Myc and P = 0.01 and P = 0.008 c-Myc S62 ).
PP2A activity can readily be assessed using two methods. PP2A is inactive when it is phosphorylated at Y 307 , and levels of PP2A Y307 phosphorylation can be measured by flow cytometry. PP2A activity assay can also be assessed directly, though this requires many cells; where cell availability was restricted the flow cytometry approach was used. Supplementary Figure 1 shows the correlation between PP2A activity assay and flow cytometry assessment of PP2A Y307 .
In vitro TKI treatment of cells from high CIP2A patients resulted in a decrease in PP2A Y307 phosphorylation and hence increased PP2A and this activity was only observed in dasatinib (P = 0.03) and nilotinib-treated cells (P = 0.04) and not with imatinib. This is consistent with our earlier in vivo observation that PP2A Y307 is not reduced following 12 months of imatinib treatment in high CIP2A patients. 5 In line with this, Figure 3f shows that in high CIP2Aexpressing K562 cells, there is a trend for 2G TKIs to increase PP2A activity to a greater degree than imatinib. Figure 3e demonstrate that these differences in TKI effects are not mediated by differential suppression of BCR-ABL activity (as assessed using the pCrKL assay 36, 40, 41 ), since all three TKIs suppress the pCrKL/ CrKL ratio to a similar degree. The differences observed were not attributable to changes in viability ( Supplementary Figure 2) .
The TKIs had no effect on CIP2A or c-Myc in patients with a low diagnostic CIP2A level. PP2A activity increased (demonstrated by decreased PP2A Y307 Figure 3d ), suggesting PP2A inhibition occurs by another mechanism, possibly involving SET. 4, 5 E2F1 acts like a control switch in the CIP2A pathway Laine et al. 8 recently demonstrated that in breast cancer, a p53mediated increase in E2F1 leads to the upregulation of CIP2A. In CML, p53 mutations only occur in about 15-20% of patients in BC and are rarely observed at diagnosis. [42] [43] [44] No patient with a high diagnostic CIP2A level had a 17p deletion or rearrangement, although the TP53 gene was not sequenced to unequivocally determine a mutation. E2F1 has previously been shown to be overexpressed in CML. 27 E2F1 was significantly higher in CML MNC compared with normal MNC (P = 0.02). E2F1 is high in patients with high diagnostic CIP2A protein levels compared with those with low CIP2A protein levels (P = 0.04, Figure 4a ). In high CIP2A patients, following 1 month of clinical 2G TKI treatment, E2F1 protein levels significantly decreased (P = 0.01, Figure 4b ) and this was accompanied by a decrease in mRNA levels of its transcriptional target CIP2A (Figure 4c ). In sharp contrast, imatinib did not suppress E2F1, and thus CIP2A mRNA levels remain unchanged. Furthermore, no difference in BCR-ABL1 mRNA expression was observed after 1 month in imatinib-or 2G TKI-treated patients.
E2F1 is stabilised by phosphorylation at S 364 and PP2A can regulate E2F1 by controlling its phosphorylation status. 8 To investigate whether E2F1 is stabilised in patients with high CIP2A protein as a consequence of impaired PP2A function, K562 cells were treated with the PP2A activator FTY720. FTY720 activates PP2A by binding and sequestering SET from PP2Ac. 22, [45] [46] [47] FTY720 increased PP2A activity (P = 0.009, Figure 4d ) and decreased CIP2A (P = 0.01, Figure 4e ). FTY720 reactivation of PP2A resulted in a decrease in E2F1 S364 (P = 0.04, Figure 4f ) leading to a decrease in total E2F1 protein (P = 0.01, Figure 4g ). These data imply that CIP2A acts to inhibit PP2A leading to stabilisation of E2F1, creating a positive feedback loop generating constant transcription and stabilisation of both CIP2A and c-Myc. This model is summarised in Figure 4h .
This putative positive feedback loop was interrogated by sequentially depleting CIP2A, c-Myc and E2F1 in K562 cells ( Supplementary Figure 3) . Inhibition of CIP2A reduced both c-Myc (P = 0.002) and E2F1 (P = 0.004). A decrease in BCR-ABL tyrosine kinase activity was also noted (data not shown). c-Myc inhibition resulted in a decrease in CIP2A (P = 0.03) and E2F1 (P = 0.003); again a decrease in BCR-ABL tyrosine kinase activity was observed. Finally E2F1 was inhibited and this caused a decrease in both CIP2A (P = 0.004) and c-Myc (P = 0.003). These data support our model in Figure 4h that a positive feedback loop exists between CIP2A/c-Myc and E2F1. We next repeated the siRNA experiments using CD34+ selected CML cells from high CIP2A patients ( Figure 5 ). Depleting CIP2A in CD34+ cells results in the reactivation of PP2A, resulting in the dephosphorylation of E2F1 and thus a decrease in E2F1 and c-Myc. This may occur by two mechanisms: first, the decrease in CIP2A level means that CIP2A can no longer stabilise c-Myc, and second the reduction in E2F1 removes its drive to transcribe c-Myc (Figures 5a and c) . In CD34+ cells, c-Myc knockdown resulted in a decrease in CIP2A (P = 0.04) and E2F1 (P = 0.04, Figures 5d and f) . This is consistent with our model (Figure 4h ), whereby decreased CIP2A will reactivate PP2A, leading to the dephosphorylation of E2F1 and therefore a decrease in E2F1. Finally E2F1 was depleted in CD34+ cells. This resulted in a decrease in CIP2A (P = 0.002) and c-Myc (Figures 5g  and i) .
Taken together, these data suggest that the E2F1 level is a major factor regulating the CIP2A/c-Myc pathway, whereby the CIP2A/c-Myc complex inhibits PP2A activity and thus E2F1 remains phosphorylated at S 364 , thereby creating a positive feedback loop. The 2G TKIs but not imatinib reduce E2F1, which controls the CIP2A/c-Myc pathway. This explains the clinical observation of Figures 1 and 2 that patients with high diagnostic CIP2A level do not progress to BC if treated with a 2G TKI as the CIP2A/c-Myc/ E2F1 pathway is suppressed.
CIP2A alters cellular proliferation rates c-Myc and E2F1 have well documented effects on proliferation, and CIP2A overexpression in neural progenitor cells increases proliferation. 48 We next examined whether high levels of CIP2A affected the rate of proliferation in CML. Inhibition of CIP2A in K562 cells by siRNA (transfection efficiency 50%) resulted in a 20% decrease in cellular proliferation (P = 0.02, Figure 6a ). Conversely, when CIP2A was overexpressed using pCMV6AC-CIP2A-GFP plasmid (transfection efficiency 70%), a 35% increase in the rate of proliferation was seen (P = 0.02, Figure 6b ). To determine if the reduction in proliferation observed when CIP2A was inhibited was a result of PP2A reactivation, K562 cells were treated with the PP2A activator FTY720. FTY720 treatment reduced the rate of CIP2A/c-Myc/E2F1 in pathway in CML Figure 6c ). Figure 6d shows that all three TKIs significantly inhibit proliferation, to a similar degree, in unmanipulated K562 cells. However, in K562 cells overexpressing CIP2A (by transfection of pCMV6-CIP2A-GFP plasmid), imatinib treatment did not alter proliferation, whereas dasatinib and nilotinib both reduced proliferation (P = 0.03 and P = 0.03, respectively, Figure 6e ). This again demonstrates a differential effect on CIP2A between imatinib vs 2G TKI.
DISCUSSION
The early identification of CML patients likely to progress and die from BC is important. CIP2A has previously been identified as a biomarker which identifies those patients likely to progress into BC, if treated with imatinib. 5 Here, we extend these observations, showing that patients with a high diagnostic CIP2A level and treated with a 2G TKI do not progress to BC, unlike those treated with imatinib. The survival and molecular outcomes of those patients with a high CIP2A level at diagnosis and treated with a 2G TKI are similar to those with a low CIP2A diagnostic level, although high CIP2A patients treated with a 2G TKI have an inferior MR4 rate than low CIP2A patients, suggesting that high CIP2A in 2G TKI-treated patients is a marker for poor molecular response.
Both dasatinib and nilotinib significantly decrease CIP2A levels in primary CML cells, and this is associated with a decrease in both c-Myc and BCR-ABL tyrosine kinase activity, and reactivation of PP2A. Imatinib did reduce the BCR-ABL tyrosine kinase activity, it did not affect CIP2A levels nor did it significantly reactivate PP2A.
The present data are consistent with a positive feedback loop within the CIP2A/c-Myc/E2F1 pathway (Figure 4h ). E2F1 is significantly higher in patients with a high diagnostic CIP2A level; this is a likely consequence of PP2A inactivation. Reactivation of PP2A by FTY720 decreases E2F1 levels. In high CIP2A patients, CIP2A stabilises c-Myc and inactivates PP2A. When PP2A is inactivated it is no longer able to dephosphorylate E2F1 thus E2F1 remains stabilised, whereby it transcriptionally activates both CIP2A and c-Myc which sustains PP2A inactivation via a positive feedback loop. Active PP2A can cause the proteasomal degradation of non-phosphorylated BCR-ABL by activating SHP1. 4 SHP1 downregulation is associated with disease progression. 49 If PP2A is inactivated by CIP2A then it will no longer be able to activate SHP1 and thus BCR-ABL remains phosphorylated and active. We have shown that FTY720 reduces CIP2A, but since FTY720 is also known to inhibit the PP2A-SET interaction [45] [46] [47] it is likely that both CIP2A and SET have a role in PP2A inhibition in CML.
Our study highlights a role for E2F1 in the CIP2A pathway, and others have shown that E2F1 is a target of BCR-ABL kinase activity and might have a role in BCR-ABL leukaemogenesis in vitro. 29, 50 Moreover, it cannot be assumed that E2F1 is the only transcription factor regulating CIP2A and others may influence this dynamic process. Furthermore, the role of E2F1 is complex, as there is a degree of redundancy between the family members and other members of the E2F family such as E2F3 have been shown to have a role in CML BC. 51 Although loss of E2F1 is generally associated with a decrease in proliferation, one study has shown that impaired DNA replication of haematopoietic progenitors in E2F1/ E2F2 mutant mice allows BCR-ABL expressing progenitors to outcompete non-mutated cells, promoting leukaemogenesis. 52 Thus, CIP2A remains an attractive therapeutic target since high levels are only found in malignant cells.
Using both K562 and CML CD34+ cells, we demonstrate that inhibition of CIP2A decreases c-Myc and reactivates PP2A, resulting in a reduction in E2F1 levels. c-Myc inhibition decreases CIP2A and reactivates PP2A, again leading to a decrease in E2F1. Furthermore, we have recently demonstrated that c-Myc inhibition of the small molecule inhibitor 10058-F4 leads to a reduction in both CIP2A and BCR-ABL tyrosine kinase activity. 53 Moreover, E2F1 inhibition results in a decrease in both CIP2A and c-Myc. These data suggest that disruption of the CIP2A/c-Myc/E2F1 interaction is important for the reactivation of PP2A and suppression of BCR-ABL.
CIP2A is known to stabilise c-Myc. c-Myc has a critical role in proliferation and cell cycle, and levels are elevated in those patients with a high diagnostic CIP2A level. 5 E2F1 results in uncontrolled cellular proliferation. 30 CIP2A has been shown to be involved in cell-cycle progression through chromosome separation and mitotic spindle dynamics, 54 supporting the notion that CIP2A has a role in proliferation. Here, we have shown that CIP2A, c-Myc and E2F1 interact and regulate each other. Inhibition of CIP2A reduces and overexpression increases proliferation, suggesting that patients with a high diagnostic CIP2A level potentially have cells which will proliferate faster. Importantly, we show that 2G TKIs but not imatinib reduce proliferation when CIP2A is overexpressed.
In those patients with a low diagnostic level of CIP2A, imatinib treatment can suppress both BCR-ABL and SET, and this leads to a degree of PP2A reactivation allowing SHP1 to dephosphorylate BCR-ABL. In patients with high prevailing CIP2A levels, their PP2A activity is suppressed to a much greater degree by both CIP2A and SET, and imatinib is unable to relieve this suppression. 2G TKIs can suppress CIP2A and E2F1, leading to reactivation of PP2A and suppression of BCR-ABL. Moreover, we show that E2F1 is elevated in high CIP2A patients and this is reduced by 2G TKIs but not imatinib. We speculate that PP2A inactivation may be the key event. When BCR-ABL is inhibited with a TKI, PP2A is reactivated and E2F1 and CIP2A are reduced. If CIP2A is inhibited by siRNA, then again PP2A is reactivated leading to a reduction in E2F1 and BCRABL.
In conclusion, our study highlights the importance of CIP2A/c-Myc/E2F1 pathway in CML. A patient with a high diagnostic CIP2A level is far less likely to progress to BC if treated with a 2G TKI from original diagnosis, because the 2G TKIs modulate the CIP2A/c-Myc/E2F1 pathway. Overall, these data suggest that if a patient has a high CIP2A level at diagnosis then they should not be treated with imatinib due to the high risk of disease progression; these patients should be offered either dasatinib or nilotinib upfront. There is therefore now a case for routine CIP2A testing at diagnosis. Further study to determine the true incidence of high CIP2A patients in the general CML population is needed. A multivariate analysis of a bigger cohort is also required to establish relationships between the high level of CIP2A and other factors in predicting response to these TKIs and clinical outcome in CML. Figure 6 . CIP2A alters the rate of proliferation. The effects of CIP2A and TKI treatment on proliferation rate was assessed in K562 cells using a BrdU assay. Each assay was performed in triplicate and the experiment was performed a minimum of three times. (a) Inhibition of CIP2A decreases proliferation (n = 4). (b) Overexpression of CIP2A using the pCMV8-CIP2A-GFP plasmid increases proliferation (n = 5). (c) FTY720 reduces proliferation (n = 4). (d) All three TKIs reduce proliferation rates significantly (n = 4). (e) CIP2A was overexpressed using the pCMV8-CIP2A-GFP and subsequently treated with imatinib, dasatinib and nilotinib. Only dasatinib and nilotinib reduced the rate of proliferation (n = 5). Statistical analysis was performed using Mann-Whitney test. Error bars represent s.e.m.
